Rheinische Friedrich-Wilhelms-Universitaet Bonn — Sponsor Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

7 Recruiting

5 Completed trials

3 Countries active

21 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II: 6 Phase III/IV: 1 Phase IV: 1 Phase I (Other): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glioblastoma 1 Subarachnoid haemorrhage 1 Oral lichen planus 1 Lichen planus 1

Top IMPs

AMINOLEVULINIC ACID HYDROCHLORIDE 1 CARBOPLATIN 1 CISPLATIN 1 DEXAMETHASONE SODIUM PHOSPHATE 1 DEXPANTHENOL 1 FLUMAZENIL 1 MECLOFENAMATE SODIUM 1 METHOTREXATE 1 NICOTINE 1 PACLITAXEL 1 VINORELBINE 1

All trials

12 total

Study on the influence of FLUMAzenil regarding the incidence of pediatric emergence delirium (ED) in children undergoing ENT surgery – FLUMA… Recruiting

2025-523543-36-00 Phase III/IV 1 country FLUMAZENIL
A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS) Recruiting

2024-515982-32-00 Phase IV 1 country
MucPreDex: Radiation-induced MUCositis PREvention using DEXpanthenol mouth rinse Recruiting

2023-510522-32-00 Phase III 1 country DEXPANTHENOL
5-Aminolevulinic Acid (5-ALA) for Intraoperative Imaging in Patients with Ovarian Cancer – a Single Center Feasibility Study (ILLUMINATE) Recruiting

2024-510614-33-00 Phase II 1 country AMINOLEVULINIC ACID HYDROCHLORIDE
Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Dur… Recruiting

2024-516367-80-00 Phase II 1 country CARBOPLATIN; CISPLATIN; PACLITAXEL; VINORELBINE
TransNiDeG Recruiting

2023-503349-71-00 Phase II 1 country NICOTINE
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy (MecMeth/ NOA-24) Recruiting

2024-511264-89-00 Phase II 1 country MECLOFENAMATE SODIUM
Effect of nucleoside reverse transcriptase inhibitors on innate immune priming Ended

2023-510378-14-00 Phase I (Other) 1 country
DEUCRALIP Ended

2022-502991-21-00 Phase II 1 country
Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended

2023-507582-25-00 Phase III 3 countries
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Methotrexate as Remission Maintenance Thera… Ended

2022-501058-12-00 Phase II 1 country METHOTREXATE
FINISHER – Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage Ended

2024-512314-17-00 Phase III 1 country DEXAMETHASONE SODIUM PHOSPHATE

Showing 1–12 of 12 trials

← All sponsors A–Z